The seven-row TL;DR
For each dimension where one drug clearly wins, we name the winner. Where the answer is "depends on your situation," the verdict text below the table explains why.
| Dimension | What the data says | Winner |
|---|---|---|
| Active ingredient | Semaglutide in both | Tie |
| FDA approval as drug product | Wegovy yes; compounded no | Wegovy |
| Cash-pay cost | $99-$249/mo (compounded) vs $199-$499/mo (NovoCare) | Compounded |
| Insurance coverage | Wegovy with PA; compounded never covered | Wegovy |
| Supply continuity in 2025-2026 | Wegovy stable; compounded semaglutide narrowed but holding | Wegovy |
| Manufacturing oversight | FDA cGMP for Wegovy; state-board oversight for 503A | Wegovy |
| Prescriber access | Most US weight loss telehealth programs prescribe both | Tie |
Verdict
If you can access Wegovy through insurance with prior authorization, choose Wegovy. The full FDA oversight, manufacturing consistency, and stable supply chain are worth the trade against compounded's lower cash price. If you cannot access insurance and NovoCare's $199-$499 is out of reach, compounded semaglutide via a transparent 503A program (Mochi, Noom Med microdose, Henry Meds) is a defensible second choice. The molecule is the same; the regulatory pathway is not.
Trial efficacy compared
The headline numbers are not from the same study, so direct comparison is approximate. The 2024 SURMOUNT-5 trial directly compared tirzepatide to semaglutide and found tirzepatide produced greater weight loss across all dose comparisons, validating the cross-trial signal.
| Compounded semaglutide | Wegovy | |
|---|---|---|
| Registration trial | STEP-1 (parent molecule, Wegovy) (NEJM, 2021) | STEP-1 (NEJM, 2021) |
| Duration | 68 weeks | 68 weeks |
| Mean weight loss (max dose) | 14.9% | 14.9% |
| Effect vs placebo | 12.4 pp | 12.4 pp |
| Patients losing ≥5% | 86.4% | 86.4% |
| Patients losing ≥15% | 50.5% | 50.5% |
2026 cash-pay cost compared
Both manufacturers run direct-to-consumer cash channels (NovoCare for Compounded semaglutide, LillyDirect for Wegovy) which are dramatically cheaper than the retail pharmacy cash price. Telehealth programs add a membership fee on top of medication cost.
| Channel | Compounded semaglutide | Wegovy |
|---|---|---|
| Retail cash | Not sold at retail; cash-pay through telehealth programs only | $1,349/mo |
| Manufacturer DTC | $99-$249/mo via telehealth programs (Mochi $99, Found $159, Noom microdose $99) | $199-$499/mo via NovoCare |
| With insurance + PA | Not covered by insurance. Compounded medications are not eligible for insurance reimbursement as drug products. | $25-$50/mo with prior authorization |
| Compounded | Cash-pay only by definition. Pricing varies $99-$249/mo depending on program. | $99-$249/mo via 503A pharmacies |
When to choose Compounded semaglutide
Choose compounded semaglutide if: (1) you have no insurance coverage and NovoCare's lowest tier is still out of reach for your budget; (2) you have selected a program with a transparent and stable 503A pharmacy partnership (Mochi or Noom microdose are the cleanest in our chart); (3) you understand the regulatory environment may tighten further; (4) you have a Plan B if the program loses pharmacy partnership mid-treatment.
When to choose Wegovy
Choose Wegovy if: (1) your insurance covers it (most commercial plans do for BMI ≥30 with PA); (2) NovoCare's $199 starter dose is sustainable; (3) you want manufacturing oversight under FDA cGMP rather than state-board oversight; (4) you want supply continuity that doesn't depend on a single 503A pharmacy partnership; (5) you want the option to switch programs without changing medication source.
Programs that prescribe each
Top Compounded semaglutide programs
Top Wegovy programs
FAQ
Is compounded semaglutide the same as Wegovy?
Is compounded semaglutide legal?
Will my insurance cover compounded semaglutide?
What if my program's compounded supply is cut off?
Can I switch from compounded to Wegovy mid-treatment?
Read the full drug profiles
Editorial disclosure
GLP Chart is an editorial comparison site. We do not dispense, prescribe, or fulfill medications. Trial data is from the cited NEJM publications. Pricing reflects publicly verified rates as of 12 May 2026. Talk to a licensed clinician about which medication is appropriate for you.